Impact BioMedical Inc.
$0.68
▼
-3.78%
2026-04-21 07:26:00
www.impactbiomedinc.com
ASE: IBO
Explore Impact BioMedical Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$67.48 M
Current Price
$0.68
52W High / Low
$1.95 / $0.36
Stock P/E
—
Book Value
$0.12
Dividend Yield
—
ROCE
-26.29%
ROE
-1.04%
Face Value
—
EPS
$-0.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
—
Debt / Equity
—
Current Ratio
0.35
Quick Ratio
0.3
Forward P/E
—
Price / Sales
2,317.48
Enterprise Value
$77.1 M
EV / EBITDA
-24.67
EV / Revenue
2,409.45
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Core market and financial snapshot is available for screening.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 2. | Turn Therapeutics Inc. | $3.38 | — | $103.07 M | — | -134.02% | -1.42% | $26.5 / $2.57 | $0.02 |
| 3. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 4. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
| 5. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 6. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 7. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.01 M | 0.02 M | 0.01 M | 0 M | 0 M | — |
| Operating Profit | -1.16 M | -0.95 M | -1.15 M | -1.01 M | -0.88 M | — |
| Net Profit | 5.25 M | -1.47 M | -14.35 M | -1.27 M | -27.11 M | — |
| EPS in Rs | 0.05 | -0.01 | -0.13 | -0.01 | -0.25 | 0.06 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.03 M | 0 M | 0 M | 0.05 M |
| Operating Profit | -4.27 M | -3.4 M | -4.03 M | -3.4 M |
| Net Profit | -11.84 M | -24.71 M | -4.34 M | -7.05 M |
| EPS in Rs | -0.11 | -0.23 | -0.04 | -0.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 17.41 M | 20.29 M | 44.63 M | 46.5 M |
| Total Liabilities | 1.85 M | 13.05 M | 16.37 M | 13.83 M |
| Equity | 12.61 M | 4.26 M | 25.22 M | 29.56 M |
| Current Assets | 0.41 M | 2.45 M | 0.33 M | 0.12 M |
| Current Liabilities | 1.16 M | 9.79 M | 13.14 M | 10.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -1.89 M | -2.85 M | -2.85 M | -2.24 M |
| Investing CF | 0 M | 0 M | -0.01 M | -0.35 M |
| Financing CF | -0.11 M | 4.85 M | 2.87 M | 2.55 M |
| Free CF | -1.89 M | -2.85 M | -2.87 M | -2.52 M |
| Capex | — | — | -0.02 M | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -469.83% | 38.51% | — | — |
| Profit Margin % | — | — | -14102% | — |
| Operating Margin % | — | — | -6808% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -12602% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.